Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00482391 · ClinicalTrials.gov registry record · Phase 2
Doxorubicin and Cyclophosphamide Followed by Paclitaxel, Trastuzumab, and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer
A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 95
- Enrollment target
NCT00482391: Completed Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00482391 is a Phase 2 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 95 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00482391, a Phase 2 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 95 participants
- Enrollment target
Study Summary
The purpose of this study is to study a new treatment for HER-2/neu (+) breast cancer.
Interventions
- DRUG cyclophosphamide
- DRUG paclitaxel
- BIOLOGICAL trastuzumab
- DRUG doxorubicin hydrochloride
- DRUG lapatinib ditosylate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 95 participants |
| Start Date | 2007-03 |
| Est. Completion | 2011-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00482391
The ClinicalTrials.gov registry entry for NCT00482391 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 95 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00482391 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00482391 about?
NCT00482391 is a clinical study titled "Doxorubicin and Cyclophosphamide Followed by Paclitaxel, Trastuzumab, and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer". The purpose of this study is to study a new treatment for HER-2/neu (+) breast cancer.
What is the current status of trial NCT00482391?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 95 participants. The study started on 2007-03. Estimated completion is 2011-07.
What interventions are being tested in trial NCT00482391?
The interventions under investigation include: cyclophosphamide (DRUG), paclitaxel (DRUG), trastuzumab (BIOLOGICAL), doxorubicin hydrochloride (DRUG), lapatinib ditosylate (DRUG).
Who is sponsoring clinical trial NCT00482391?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.